The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell Therapy Manufacturing Market (2nd Edition), 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    July 2018

  • Pages
    444

  • View Count
    6731

Example Insights

An updated edition is available at the following link

View 3rd edition

 

Overview

The average cost of manufacturing a cell therapy based product depends on multiple parameters, such as duration of manufacturing, and whether it involves a vector or is gene modified, among others. The industry estimates range from USD 2,000 for cartilage implant products to USD 50,000-60,000 for cell and gene therapy products

-Chief Executive Officer, an Australia based CMO

Cell-based therapies have gained significant attention in the overall biopharmaceutical industry. The personalized nature of these treatment options render them highly specific and, according to a number of clinical studies, safe and efficacious. Such therapies are considered to possess the potential to address various unmet medical needs associated with the treatment of several types of physiological disorders and clinical conditions. A number of pharmaceutical companies and investors have already invested significant capital towards the development and commercialization of such products. Around 20 such therapies have been approved; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also worth highlighting that over 500 cell-based therapy candidates are in different stages of clinical development, and are being evaluated in more than 1,000 active clinical studies across various regions of the globe.

The growing number of cell therapy candidates, coupled to their rapid progression through various phases of clinical development, continues to create an increasing demand for facilities that offer manufacturing services for these complex therapies. There is a wide array of industry players, including well-established companies, mid-sized firms and start-ups, as well as academic institutes that are significantly contributing to the production of GMP grade cell therapies. In addition, several players offer novel technology solutions, aimed at improving and upgrading existing cell-based therapies and their manufacturing processes. Most of these players have signed multiple partnerships / collaborations with an aim to optimize, scale-up and expand the capabilities for the production of cell-based therapies. Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums, to accelerate the transition of these therapies from laboratories to clinics. Looking at the evolutionary trend so far, we believe that the cell therapy manufacturing market is poised to steadily grow, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by the conventional methods of production.

 

Scope of the Report

The “Cell Therapy Manufacturing Market (2nd Edition), 2018-2030” report provides an extensive study of the rapidly growing market of cell therapy manufacturing, focusing on contract manufacturers, as well as cell therapy developers with in-house manufacturing facilities. The study presents an in-depth analysis of various organizations that are engaged in this domain across different regions of the globe. Amongst other elements, the report includes:

  • A review of the current status of the market with respect to key players, along with information on the location of their manufacturing facilities, scale of production, type of cells manufactured (immune cells (such as T cells, dendritic cells, NK cells), stem cells (such as adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), purpose of production (fulfilling in-house requirements / as a contract service provider), type of organization (industry / non-industry), source of cell-based therapies (autologous / allogeneic), cGMP regulatory compliance, and availability of fill / finish services for cell-based therapies.
  • A discussion on roadmaps published by different agencies across the globe to provide strategies to advance cell therapy manufacturing.
  • Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies; each profile presents an overview of the company, information on its manufacturing facilities, and recent collaborations.
  • A discussion on the role of non-profit organizations that have aided in the advancement of cell-based therapies, as well as manufacturing processes.
  • Detailed information on the role of automation technologies in improving current manufacturing methods, along with a qualitive comparative analysis of cost differences between manual and automated processes.
  • An analysis of the recent collaborations (signed since 2014) focused on the manufacturing of cell-based therapies; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, and scale of operation (clinical and / or commercial).
  • An estimate of the overall installed capacity for manufacturing cell-based therapies of various organizations, based on information reported by industry stakeholders in the public domain (wherever available) and affiliated data collated via both secondary and primary research. The analysis highlights the distribution of the global capacity of industry and non-industry players on the basis of scale of operation (clinical and commercial), regions (North America, EU and Asia Pacific) and size of the organization (small-sized, mid-sized and large-sized organizations).
  • An analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies.
  • An in-depth analysis of the cell-based therapy manufacturers, featuring three schematic representations; these include [A] a three dimensional grid analysis, representing the distribution of cell-based therapy manufacturers on the basis of the type of cells manufactured, scale of operation and purpose of production (in-house operations / contract manufacturing services), [B] a logo landscapes of cell therapy manufacturers based on the type of cells manufactured, geographical location (North America, EU and Asia Pacific) and the type / size of organization (non-industry players, and small-sized, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of cell therapy manufacturing facilities of industry and non-industry stakeholders.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of cell-based therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2018-2030. In addition, to account for the uncertainties associated with the manufacturing of cell-based therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with

  • Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy)
  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Gerard MJ Bos (Chief Executive Officer, CiMaas)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified

Contents

Chapter 2  is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the cell-based therapy manufacturing market in the short to mid-term, and long term.

Chapter 3  provides a general introduction to the cell-based therapies and ATMPs. It includes a detailed discussion on the manufacturing process of cell-based therapies, associated challenges, and applications of currently available cell therapies. It also provides information on the manufacturing models (centralized and decentralized) that are being considered for the production of cell-based therapies, along with a discussion on their advantages and disadvantages. Further, it provides details on the scalability of these cell-based therapies. The chapter also includes a brief overview on the role of automation and supply chain management with respect to cell-based therapies.

Chapter 4  featuresa list ofall the contract service providers / in-house manufacturers that are actively involved in the manufacturing of cell-based therapies. It provides information on the type of organizations and the geographic location of their facilities, and details on their cell-based therapy manufacturing capabilities, specifically focusing on scale of operation, type of cells manufactured, purpose of manufacturing (in-house requirement / contract manufacturing), source of cells (autologous / allogeneic) and availability of fill / finish services.

Chapter 5  provides a detailed description on the regulatory landscape related to cell therapies across various geographies, such as the US, Europe and other regions. Further, it presents an analysis of the manufacturing facilities on basis of the certifications awarded (for manufacturing cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6  describes the strategies that are likely to be adopted to accelerate the translation of cell-based therapies from laboratory to clinics.It provides details on roadmaps published by different organizations in various geographies, specifically in the US.

Chapter 7  discusses the role of automation technologies that are likely to optimize the current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices. It also presents a qualitive analysis of the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their production processes.  

Chapter 8  offers detailed profiles of industry players that offer contract manufacturing services at the clinical and / or commercial scales. Each profile provides a brief overview of the company, details on its manufacturing capabilities and facilities, and the relevant collaborations that have been inked over the last few years.

Chapter 9  offers profiles of the non-industry players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on manufacturing capabilities and facilities.

Chapter 10  discusses the role of non-profit organizations in this domain. It provides a list of organizations that are actively involved in the development and production of cell-based therapies, across different global regions. Further, it includes profiles of organizations that provide financial and / or technological support to cell therapy manufacturers and developers. Additionally, the chapter provides information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community. 

Chapter 11  features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players in this market. It includes a brief description on the various types of partnership models (which include manufacturing agreements, technology upgrade and manufacturing process development and testing agreements, additional services agreements, joint ventures and acquisitions) that are employed by stakeholders in this domain, and analysis on the trend of partnerships inked since 2014. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of cell-based therapies. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12  features a comprehensive analysis of the overall installed capacity of cell-based therapy manufacturers. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small-sized, mid-sized and large-sized companies, and non-industry players distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the cell-based therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, EU, Asia Pacific and the rest of the world) and size of the organization (small-sized, mid-sized and large-sized organizations).

Chapter 13  highlights our views on the various factors, including manufacturing costs, that may be taken into consideration while pricing cell-based therapies. It features discussions on different pricing models / approaches, which a manufacturer may choose to adopt to decide the price of its proprietary products.

Chapter 14  presents a comprehensive market forecast analysis, highlighting the likely growth of the cell therapy manufacturing market till the year 2030. We have segregated the opportunity by scale of operation (clinical and commercial), type of cell therapy (T-cell immunotherapies, dendritic cell-based therapies, stem cell therapies and other ATMPs), source of cells (autologous and allogeneic) and geography (North America, EU and Asia Pacific).

Chapter 15  presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of cell-based therapy manufacturers on the basis of type of cells manufactured, scale of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of two logo landscapes, representing the distribution of cell-based therapy manufacturers based on the type of cells manufactured (immune cells and stem cells), geographical regions (North America, EU and Asia Pacific) and the type / size of organization (non-industry, small-sized, mid-sized and large companies). The chapter also consists of two schematic world map representations to highlight the locations of various cell-based therapy manufacturing facilities across different continents.

Chapter 16  provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of cell therapy manufacturing, under a comprehensive SWOT framework.

Chapter 17  summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 18  presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development and / or manufacturing of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 19  is a collection of interview transcripts of the discussions held with key stakeholders in the industry.We have presented details of interviews held with Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy), Tim Oldham (Chief Executive Officer, Cell Therapies), Gerard MJ Bos (Chief Executive Officer, CiMaas), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

Chapter 20  is an appendix, which provides tabulated data and numbers for all the figures in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Context and Background
3.2. An Introduction to Cell-based Therapies
3.2.1. Comparison of Cell-based Therapies and Biotechnology Products
3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
3.2.3. Current Market Landscape
 
3.3. An Overview to Cell Therapy Manufacturing
3.4. Cell Therapy Manufacturing Models
3.4.1. Centralized Manufacturing Model
3.4.2. Decentralized Manufacturing Model
3.5. Scalability of Cell Therapy Manufacturing Processes
3.5.1. Scale-up
3.5.2. Scale-out
 
3.6. Types of Cell Therapy Manufacturers
3.7. Key Challenges for Manufacturing Cell Therapies
3.8. Important Factors for Cell Therapy Manufacturing
3.9. Automation of Cell Therapy Manufacturing Processes
3.10. Supply Chain for Cell Therapy Manufacturing
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cell Therapy Manufacturers: Overall Market Landscape
4.2.1. Distribution by Location of Headquarters
4.2.2. Distribution by Location of Manufacturing Facility
4.2.3. Distribution by Type of Cells Manufactured
4.2.4. Distribution by Purpose of Production
4.2.5. Distribution by Scale of Operation
4.2.6. Distribution by Source of Cells
4.2.7. Distribution by Type of Cell Cultures
4.3. Cell Therapy Manufacturing: Role of Logistics Service Providers
 
5. REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory System in the US
5.2.2. Regulatory System in Europe
5.2.3. Regulatory System in Japan
5.2.4. Conditional Approvals
 
5.3. Accreditations for Cell Therapy Manufacturing
5.3.1. Information on Facility Approvals Granted by Various Regulatory Authorities
5.4. Guidelines for Manufacturing Cell-based Therapies
5.5. Existing Challenges
5.5.1. Variability in Regulatory Guidelines across Different Geographies
 
6. ROADMAPS: POTENTIAL STRATEGIES TO OVERCOME EXISTING CHALLENGES
6.1. Chapter Overview
6.2. Roadmap for the US
6.2.1. Cell Processing
6.2.2. Cell Preservation, Distribution and Handling
6.2.3. Process Automation and Data Analytics
6.2.4. Process Monitoring and Quality Control
6.2.5. Standardization and Regulatory Support
6.2.6. Workforce Development
6.2.7. Supply Chain and Transport Logistics
 
6.3. Roadmaps for Other Geographies
6.3.1. Europe
6.3.2. Asia Pacific
 
7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
7.1. Chapter Overview
7.2. Automation of Cell Therapy Processes
7.2.1. Closed Systems
7.2.2. Single-use Systems
7.2.3. Modular Systems
7.3. Roadmap for Developing an Automated Device
7.4. GMP-in-a-Box Concept
7.5. List of Service Providers for Automation of Manufacturing Processes
7.6. Comparative Analysis of Manual and Automated Processes
 
8. CELL THERAPY MANUFACTURING: INDUSTRY PLAYERS
8.1. Chapter Overview
8.2. Market Landscape in the US
8.2.1. Brammer Bio
8.2.1.1. Company Overview
8.2.1.2. Service Portfolio
8.2.1.3. Manufacturing Capabilities
8.2.1.4. Partnerships
 
8.2.2 Cognate BioServices
8.2.2.1. Company Overview
8.2.2.2. Service Portfolio
8.2.2.3. Manufacturing Capabilities
8.2.2.4. Partnerships
 
8.2.3. FUJIFILM Cellular Dynamics
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Manufacturing Capabilities
8.2.3.4. Partnerships
 
8.2.4. KBI Biopharma
8.2.4.1. Company Overview
8.2.4.2. Service Portfolio
8.2.4.3. Manufacturing Capabilities
 
8.2.5 PCT, a Hitachi Group Company
8.2.5.1. Company Overview
8.2.5.2. Service Portfolio
8.2.5.3. Manufacturing Capabilities
8.2.5.4. Partnerships
 
8.2.6. Waisman Biomanufacturing
8.2.6.1. Company Overview
8.2.6.2. Service Portfolio
8.2.6.3. Manufacturing Capabilities
8.2.6.4. Partnerships
 
8.3. Market Landscape in Europe
8.3.1. BioNTech Innovative Manufacturing Services
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.3. Manufacturing Capabilities
8.3.1.4. Partnerships
 
8.3.2. Cell and Gene Therapy Catapult
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.3. Manufacturing Capabilities
8.3.2.4. Partnerships
 
8.3.3. CELLforCURE
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.3. Manufacturing Capabilities
8.3.3.4. Partnerships
 
8.3.4. Lonza
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.3. Manufacturing Capabilities
8.3.4.4. Partnerships
 
8.3.5. MaSTherCell
8.3.5.1. Company Overview
8.3.5.2. Service Portfolio
8.3.5.3. Manufacturing Capabilities
8.3.5.4. Partnerships
 
8.3.6. Roslin Cell Therapies
8.3.6.1. Company Overview
8.3.6.2. Service Portfolio
8.3.6.3. Manufacturing Capabilities
8.3.6.4. Partnerships
 
8.4. Market Landscape in Asia Pacific
8.4.1. Cell Therapies
8.4.1.1. Company Overview
8.4.1.2. Service Portfolio
8.4.1.3. Manufacturing Capabilities
8.4.1.4. Partnerships
 
8.4.2. Cryosite
8.4.2.1. Company Overview
8.4.2.2. Service Portfolio
8.4.2.3. Manufacturing Capabilities
8.4.2.4. Partnerships
 
8.4.3. Japan Tissue Engineering (J-TEC)
8.4.3.1. Company Overview
8.4.3.2. Service Portfolio
8.4.3.3. Manufacturing Capabilities
8.4.3.4. Partnerships
 
8.4.4. MEDINET
8.4.4.1. Company Overview
8.4.4.2. Service Portfolio
8.4.4.3. Manufacturing Capabilities
8.4.4.4. Partnerships
 
8.4.5. Nikon CeLL innovation
8.4.5.1. Company Overview
8.4.5.2. Service Portfolio
8.4.5.3. Manufacturing Capabilities
8.4.5.4. Partnerships
 
8.4.6. WuXi Advanced Therapies, a subsidiary of WuXi AppTec
8.4.6.1. Company Overview
8.4.6.2. Service Portfolio
8.4.6.3. Manufacturing Capabilities
8.4.6.4. Partnerships
 
9. CELL THERAPY MANUFACTURING: NON-INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
9.2.1. Overview
9.2.2. Operating Segments
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities
 
9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
9.3.1. Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities
 
9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
9.4.1. Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities
 
9.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
9.5.1. Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities
 
9.6. Laboratory for Cell and Gene Medicine, Stanford University
9.6.1. Overview
9.6.2. Manufacturing Facilities and Capabilities
 
9.7. Molecular and Cellular Therapeutics, University of Minnesota
9.7.1. Overview
9.7.2. Service Portfolio
9.7.3. Manufacturing Facilities and Capabilities
 
9.8. Newcastle Cellular Therapies Facility, Newcastle University
9.8.1. Overview
9.8.2. Service Portfolio
9.8.3. Manufacturing Facilities and Capabilities
 
9.9. Rayne Cell Therapy Suite, King’s College London
9.9.1. Overview
9.9.2. Manufacturing Facilities and Capabilities
 
9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine
9.10.1. Overview
9.10.2. Manufacturing Facilities and Capabilities
 
9.11. Sydney Cell and Gene Therapy
9.11.1. Overview
9.11.2. Manufacturing Facilities and Capabilities
 
10. ROLE OF NON-PROFIT ORGANIZATIONS
10.1. Chapter Overview
10.2. Cell Therapy Manufacturing: Non-Profit Organizations
10.2.1. CellCAN
10.2.2. Cell Therapy Manufacturing Cooperative Research Center
10.2.3. National Cell Manufacturing Consortium
10.2.4. California Institute of Regenerative Medicine
10.3. Cell Therapy Manufacturing: International Societies
 
11. RECENT DEVELOPMENTS
11.1. Chapter Overview
11.2. Partnership / Collaboration Models
11.3. Cell Therapy Manufacturing: List of Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership Model
11.3.3. Analysis by Year and Type of Partnership Model
11.3.4. Analysis by Type of Cells
11.3.5. Most Active Players: Analysis by Number of Partnerships
11.3.6. Regional Distribution
 
12. CAPACITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology for Industry Players
12.2.1 Cell Therapy Manufacturing: Installed Global Capacity in Terms of Number of Cleanrooms
12.2.1.1. Distribution by Size of Manufacturers
12.2.1.2. Distribution by Scale of Operation
12.2.1.3. Distribution by Location of Manufacturing Facilities
12.2.2. Cell Therapy Manufacturing: Installed Global Capacity in Terms of Cleanroom Area
12.2.2.1. Distribution by Size of Manufacturers
12.2.2.2. Distribution by Scale of Operation
12.2.2.3. Distribution by Location of Manufacturing Facilities
12.3. Key Assumptions and Methodology for Non-Industry Players
12.3.1. Cell Therapy Manufacturing: Installed Global Capacity in Terms of Number of Cleanrooms
12.3.1.1. Distribution by Scale of Operation
12.3.1.2. Distribution by Location of Manufacturing Facilities
12.3.2. Cell Therapy Manufacturing: Installed Global Capacity in Terms of Cleanroom Area
12.3.2.1. Distribution by Scale of Operation
12.3.2.2. Distribution by Location of Manufacturing Facilities
12.4 Concluding Remarks
 
13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing Towards High Price Tags of Cell-based Therapies
13.3. Pricing Models for Cell-based Therapies
13.3.1. On the Basis of Associated Costs for T-Cell Immunotherapies
13.3.2. On the Basis of Associated Costs for Stem Cell Therapies
13.3.3. On the Basis of Competition
13.3.4. On the Basis of Patient Segment
13.3.5. On the Basis of Expert Opinions
13.4. Cost Control for Cell Therapy Products
13.4.1. Cost of Goods Sold
13.4.2. Manufacturing Cost-Effective Therapies with Automation
13.4.3. Role of Cell Therapy Contract Manufacturing Organizations
 
14. MARKET SIZING AND FORECAST
14.1. Chapter Overview
14.2. Scope of the Forecast
14.3. Forecast Methodology
14.4. Input Tables and Key Assumptions
14.5. Overall Cell Therapy Manufacturing Market, 2018-2030
14.5.1. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Type of Cell Therapy
14.5.2. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Source of Cells
14.5.3. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Scale of Operation
14.5.4. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Purpose of
Manufacturing
14.5.5. Cell Therapy Manufacturing Market, 2018-2030: Distribution by Regions
 
14.6. Market Opportunity for Commercial Scale Manufacturing of Cell-based Therapies
14.6.1. T-cell Therapy Market
14.6.1.1. Commercial Scale Manufacturing Market for T-cell Therapies, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
14.6.1.2. Commercial Scale Manufacturing Market for T-cell Therapies, 2018-2030: Distribution by Source of Cells
14.6.1.3. Commercial Scale Manufacturing Market for T-cell Therapies, 2018-2030: Distribution by Regions
 
14.6.2. Dendritic Cell and Tumor Cell Therapy Market
14.6.2.1. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
14.6.2.2. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030: Distribution by Source of Cells
14.6.2.3. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030 : Distribution by Regions
 
14.6.3. Stem Cell Therapy Market
14.6.3.1. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2018-2030: Distribution by Source of Cells
14.6.3.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2018-2030: Distribution by Regions
 
14.7. Market Opportunity for Clinical Scale Manufacturing of Cell-based Therapies
14.7.1. T-cell Therapy Market
14.7.1.1. Clinical Scale Manufacturing Market for T-cell Therapies, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
14.7.1.2. Clinical Scale Manufacturing Market for T-cell Therapies, 2018-2030: Distribution by Source of Cells
14.7.1.3. Clinical Scale Manufacturing Market for T-cell Therapies, 2018-2030: Distribution by Regions
 
14.7.2. Dendritic Cell and Tumor Cell Therapy Market
14.7.2.1. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
14.7.2.2. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030: Distribution by Source of Cells
14.7.2.3. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2018-2030: Distribution by Regions
 
14.7.3. Stem Cell Therapy Market
14.7.3.1. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2018-2030: Distribution by Source of Cells
14.7.3.2. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2018-2030: Distribution by Regions
 
15. KEY INSIGHTS
15.1. Cell Therapy Manufacturers: World Map Representation by Location of Manufacturing Facility
15.1.1. Industry Players
15.1.2. Non- Industry Players
15.2. Cell Therapy Manufacturers: Grid Analysis
15.3. Cell Therapy Manufacturers: Logo Landscapes by Type of Cell Therapy
15.3.1. Immune Cells
15.3.2. Stem Cells
 
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
16.7. Concluding Remarks
 
17. CONCLUSION
17.1. Owing to a Consistently Growing Pipeline, the Demand for Cell Therapy Manufacturing Services is Likely to Increase Steadily
17.2. The Market Features the Involvement of Several Industry, as well as Academic Players; we anticipate Trend to Persist in the Future as well
17.3. Stakeholders have Established their Presence across Different Regions; Presently, the US and UK are Considered as Prominent Hubs for Cell Therapy Manufacturing
17.4. Partnering Activity is on the Rise as Organizations Actively Collaborate to Develop Novel Technology Platforms and Improve Current Manufacturing Processes
17.5. Technical Advances Enabling Automation, Scale-up and Better Logistics Solutions are Expected to Act as Key Growth Drivers
17.6. Cell Therapy Manufacturing is Projected to become a Multi-billion Dollar Market over the Coming Decade
 
18. SURVEY ANALYSIS
18.1. Chapter Overview
18.2. Seniority Level of Respondents
18.3. Type of Cell Therapy
18.4. Scale of Operation
18.5. Source of Cells
18.6. Type of Cell Culture System
18.7. Availability of Fill / Finish Services
 
19. INTERVIEW TRANSCRIPTS
19.1. Chapter Overview
19.2. Cell Therapies
19.2.1. Company Overview
19.2.2. Interview Transcript: Tim Oldham, Chief Executive Officer
 
19.3. Center of Excellence for Cellular Therapy / C3i
19.3.1. Company Overview
19.3.2. Interview Transcript: Arnaud Deladeriere, Manager, Business Development & Operations-cGMP Manufacturing Unit
 
19.4. CiMaas
19.4.1. Company Overview
19.4.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer
 
19.5. Lion TCR
19.5.1. Company Overview
19.5.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
 
19.6. Waisman Biomanufacturing
19.6.1. Company Overview
19.6.2. Interview Transcript: Brian Dattilo, Manager of Business Development
 
19.7. YposKesi
19.7.1. Company Overview
19.7.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development
 
20. APPENDIX: TABULATED DATA
 
21. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Classification of Advanced Therapy Medicinal Products
Figure 3.2  Steps for Manufacturing Cell Therapies 
Figure 3.3  Centralized Manufacturing: Process Model
Figure 3.4  Decentralized Manufacturing: Process Model
Figure 3.5  Cell Therapy Manufacturing: Types of Manufacturers
Figure 3.6  Cell Therapies: Challenges and Drivers
Figure 3.7  Cell Therapies: Potency as Critical Quality Attribute
Figure 3.8  Cell Therapy Manufacturing: Supply Chain Model
Figure 3.9  Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 4.1  Cell Therapy Manufacturers: Distribution by Location of Headquarters
Figure 4.2  Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 4.3  Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.4  Cell Therapy Manufacturers: Distribution by Type of Organization
Figure 4.5  Cell Therapy Manufacturers: Distribution by Type of Cells Manufactured
Figure 4.6  Cell Therapy Manufacturers: Distribution by Immune Cells
Figure 4.7  Cell Therapy Manufacturers: Distribution by Stem Cells
Figure 4.8  Cell Therapy Manufacturers: Distribution by Purpose of Production
Figure 4.9  Cell Therapy Manufacturers: Distribution by Scale of Operation
Figure 4.10  Cell Therapy Manufacturers: Distribution by Source of Cells
Figure 5.1  Cell Therapy Manufacturing: Distribution by Regulatory Authorities
Figure 6.1  Cell Therapy Manufacturing: Roadmap for the US
Figure 6.2  Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
Figure 7.1  Probable Automation Approaches for Various Stages of Manufacturing Process
Figure 7.2  Different Types of Systems Used for Cell Therapy Manufacturing
Figure 7.3  Requirements to Implement Closed Systems in Cell Therapy Manufacturing  Processes
Figure 7.4  Advantages and Disadvantages of Single-Use System
Figure 7.5  Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 7.6  Cell Therapy Manufacturing: Comparative Analysis of Manual versus Automated Processes
Figure 7.7  Cell Therapy Manufacturing: Comparative Analysis of Manual versus Automated Processes Based on the Annual Cost
Figure 7.8  Cell Therapy Manufacturing: Comparative Analysis of Manual versus Automated Processes Based on Cost of Manufacturing per Batch
Figure 8.1  Brammer Bio: Service Portfolio 
Figure 8.2  Cognate BioServices: Service Portfolio
Figure 8.3  FUJIFILM Cellular Dynamics: Service Portfolio 
Figure 8.4  KBI Biopharma: Service Portfolio  
Figure 8.5  PCT: Company Structure 
Figure 8.6  PCT: Service Portfolio
Figure 8.7  Waisman Biomanufacturing: Service Portfolio  
Figure 8.8  Waisman Biomanufacturing: Clinical Products Portfolio
Figure 8.9  Waisman Biomanufacturing: Quality Assurance and Control   
Figure 8.10  Waisman Biomanufacturing: Manufacturing Suites 
Figure 8.11  Waisman Biomanufacturing: Overview of Suite Services 
Figure 8.12  BioNTech Innovative Manufacturing Services: Service Portfolio 
Figure 8.13  Cell and Gene Therapy Catapult: Service Portfolio 
Figure 8.14  CELLforCURE: Service Portfolio 
Figure 8.15  Lonza: Historical Timeline 
Figure 8.16  Lonza: Sub-Segments 
Figure 8.17  Lonza Pharma and Biotech: Service Portfolio
Figure 8.18  Lonza: Biological Manufacturing Services 
Figure 8.19  Lonza: Cellular Products
Figure 8.20  Lonza Netherlands: Service Portfolio 
Figure 8.21  MaSTherCell: Service Portfolio 
Figure 8.22  Roslin Cell Therapies: Service Portfolio 
Figure 8.23  Cell Therapies: Service Portfolio 
Figure 8.24  Cryosite: Service Portfolio 
Figure 8.25  Japan Tissue Engineering: Service Portfolio 
Figure 8.26  MEDINET: Service Portfolio 
Figure 8.27  Nikon CeLL innovation: Service Portfolio
Figure 9.1  Center for Cell and Gene Therapy: Operating Segments
Figure 9.2  Center for Cell and Gene Therapy: Service Portfolio
Figure 9.3  Center for Cell Manufacturing Ireland: Service Portfolio
Figure 9.4  Molecular and Cellular Therapeutics: Service Portfolio
Figure 9.5  Newcastle Cellular Therapies Facility: Service Portfolio
Figure 11.1  Cell Therapy Manufacturing Partnerships: Cumulative Trend by Year (2014-2018)
Figure 11.2  Cell Therapy Manufacturing Partnerships: Distribution by Type of Partnership Model
Figure 11.3  Cell Therapy Manufacturing Partnerships: Distribution by Year and Type of Partnership Model (2014-2018)
Figure 11.4  Cell Therapy Manufacturing Partnerships: Distribution by Type of Cells
Figure 11.5  Cell Therapy Manufacturing Partnerships: Distribution by Most Active Players
Figure 11.6  Cell Therapy Manufacturing Partnerships: Regional Distribution
Figure 11.7  Cell Therapy Manufacturing: Regional Distribution by Intercontinental and Intracontinental 
Agreements
Figure 12.1  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Size of  Manufacturers (Sample Data Set for Industry Players)
Figure 12.2  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Range of Installed Capacity
Figure 12.3  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Size of Manufacturers
Figure 12.4  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Figure 12.5  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facility
Figure 12.6  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area: Distribution by Size of Manufacturers (Sample Data Set for Industry Players)
Figure 12.7  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Range of Installed Capacity
Figure 12.8  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Size of Manufacturers
Figure 12.9  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Figure 12.10  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facility
Figure 12.11  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Range of Installed Capacity
Figure 12.12  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Figure 12.13  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facility
Figure 12.14 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Range of Installed Capacity
Figure 12.15  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Figure 12.16  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facility
Figure 13.1  Targeted Therapies: Pricing Model Based on Patient Segment
Figure 14.1 Overall Cell Therapy Manufacturing Market, Base Scenario, 2018-2030 (USD Billion)
Figure 14.2 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Type of Cell Therapy, 2018, 2025 and 2030
Figure 14.3 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Source of Cells,  2018, 2025 and 2030
Figure 14.4 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Scale of Operation, 2018, 2025 and 2030
Figure 14.5  Cell Therapy Manufacturing Market, 2018-2030: Distribution by Purpose of 
Manufacturing, 2018, 2025 and 2030 
Figure 14.6  Cell Therapy Manufacturing Market, 2018-2030: Distribution by Regions, 2018, 2025 and 2030
Figure 14.7  Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
Figure 14.8  Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells
Figure 14.9  Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Regions
Figure 14.10  Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
Figure 14.11  Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells
Figure 14.12  Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions
Figure 14.13  Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells
Figure 14.14  Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions
Figure 14.15  Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
Figure 14.16  Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells
Figure 14.17  Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2018-2030: Distribution by Regions
Figure 14.18  Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
Figure 14.19  Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells
Figure 14.20  Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions
Figure 14.21  Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Source of Cells
Figure 14.22  Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2018-2030: Distribution by Regions
Figure 15.1  Cell Therapy Manufacturer: Regional Distribution by Location of Manufacturing Facility of Industry Players, World Map Representation
Figure 15.2  Cell Therapy Manufacturing: Regional Distribution by Location of Manufacturing Facility of Non-Industry Players, World Map Representation 
Figure 15.3  Cell Therapy Manufacturing: Grid Analysis by Type of Manufacturer and Scale of Operation
Figure 15.4  Cell Therapy Manufacturing: Logo Landscape, Immune Cells
Figure 15.5  Cell Therapy Manufacturing: Logo Landscape, Stem Cells
Figure 16.1  Cell Therapy Manufacturing: SWOT Analysis
Figure 16.2  Comparison of SWOT Factors: Harvey Ball Analysis
Figure 17.1  Cell Therapy Manufacturing Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Figure 18.1  Survey Analysis: Distribution by Type of Organization
Figure 18.2  Survey Analysis: Distribution by Location of Manufacturing Facility
Figure 18.3  Survey Analysis: Distribution by Seniority Level of Respondents
Figure 18.4  Survey Analysis: Distribution by Type of Cell Therapy
Figure 18.5  Survey Analysis: Distribution by Scale of Manufacturing
Figure 18.6  Survey Analysis: Distribution by Source of Cells
Figure 18.7  Survey Analysis: Distribution by Cell Culture System
Figure 18.8  Survey Analysis: Distribution by Fill / Finish Service 

List of Tables

Table 3.1  Cell-based Therapies: Applications
Table 3.2  Differences between Cell Therapy and Biotechnology Products
Table 3.3  Cell-based Therapies: Commercialized Products
Table 3.4  Assessment Strategies for Different Manufacturing Processes
Table 3.5  Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 4.1  List of Cell Therapy Manufacturers
Table 4.2  Cell Therapy Manufacturers: Type of Cells Manufactured 
Table 4.3  Cell Therapy Manufacturers: Purpose of Production
Table 4.4  Cell Therapy Manufacturers: Scale of Operation
Table 4.5  Cell Therapy Manufacturers: Source of Cells
Table 4.6  Cell Therapy Manufacturers: Type of Cell Cultures
Table 4.7  Logistics Service Providers for Cell-based Therapies
Table 5.1  Cell Therapy Manufacturing: Regulatory Authorities
Table 5.2  Cell Therapy Manufacturing: Regulatory Considerations
Table 6.1  Cell Processing: Challenges and Strategies
Table 6.2  Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 6.3  Process Monitoring and Quality Control: Challenges and Strategies
Table 6.4  Standardization and Regulatory Support: Challenges and Strategies
Table 6.5  Workforce Development: Challenges and Strategies
Table 6.6  Supply Chain and Transport Logistics: Challenges and Strategies
Table 7.1  Cell Therapy Manufacturing: List of Service Providers for Automation of Manufacturing Process
Table 7.2  Cell Therapy Manufacturing: Comparative Analysis of Manual versus Automated Processes Based on Scale-up Scenario
Table 8.1  Brammer Bio: Company Overview 
Table 8.2  Brammer Bio: Overview of Manufacturing Capabilities 
Table 8.3  Brammer Bio: Partnerships
Table 8.4  Cognate BioServices: Company Overview 
Table 8.5  Cognate BioServices: Overview of Manufacturing Capabilities 
Table 8.6  Cognate BioServices: Partnerships
Table 8.7  FUJIFILM Cellular Dynamics: Company Overview 
Table 8.8  FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities 
Table 8.9  FUJIFILM Cellular Dynamics: Partnerships
Table 8.10  KBI Biopharma: Company Overview 
Table 8.11  KBI Biopharma: Overview of Manufacturing Capabilities 
Table 8.12  PCT: Company Overview 
Table 8.13  PCT: Overview of Manufacturing Capabilities
Table 8.14  PCT: Partnerships
Table 8.15  Waisman Biomanufacturing: Company Overview 
Table 8.16  Waisman Biomanufacturing: Overview of Manufacturing Capabilities 
Table 8.17  Waisman Biomanufacturing: Partnerships
Table 8.18  BioNTech Innovative Manufacturing Services: Company Overview 
Table 8.19  BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities 
Table 8.20  BioNTech Innovative Manufacturing Services: Partnerships
Table 8.21 Cell and Gene Therapy Catapult: Company Overview 
Table 8.22  Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities 
Table 8.23  Cell and Gene Therapy Catapult: Partnerships
Table 8.24  CELLforCURE: Company Overview 
Table 8.25  CELLforCURE: Overview of Manufacturing Capabilities
Table 8.26  CELLforCURE: Partnerships
Table 8.27  Lonza: Company Overview
Table 8.28  Lonza: Global Manufacturing Sites
Table 8.29  Lonza: Overview of Manufacturing Capabilities
Table 8.30  Lonza: Partnerships
Table 8.31  MaSTherCell: Company Overview
Table 8.32  MaSTherCell: Overview of Manufacturing Capabilities
Table 8.33  MaSTherCell: Partnerships
Table 8.34  Roslin Cell Therapies: Company Overview 
Table 8.35  Roslin Cell Therapies: Overview of Manufacturing Capabilities
Table 8.36  Roslin Cell Therapies: Partnerships
Table 8.37  Cell Therapies: Company Overview 
Table 8.38  Cell Therapies: Overview of Manufacturing Capabilities 
Table 8.39  Cell Therapies: Partnerships
Table 8.40  Cryosite: Company Overview 
Table 8.41  Cryosite: Overview of Manufacturing Capabilities 
Table 8.42  Cryosite: Partnerships
Table 8.43  Japan Tissue Engineering: Company Overview 
Table 8.44  Japan Tissue Engineering: Overview of Manufacturing Capabilities
Table 8.45  Japan Tissue Engineering: Partnerships 
Table 8.46  MEDINET: Company Overview 
Table 8.47  MEDINET: Overview of Manufacturing Capabilities 
Table 8.48  Nikon CeLL innovation: Company Overview 
Table 8.49  Nikon CeLL innovation: Overview of Manufacturing Capabilities
Table 8.50  Nikon CeLL innovation: Partnerships
Table 8.51  WuXi Advanced Therapies: Company Overview 
Table 8.52  WuXi Advanced Therapies: Overview of Manufacturing Capabilities 
Table 8.53 WuXi Advanced Therapies: Partnerships   
Table 9.1  Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities 
Table 9.2  Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities 
Table 9.3  Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.4  Guy’s and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities 
Table 9.5  Laboratory of Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
Table 9.6  Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
Table 9.7  Newcastle Cellular Therapies Facility: Overview of Manufacturing Facilities and Capabilities 
Table 9.8  Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
Table 9.9  Scottish National Blood Transfusion Services: Overview of Manufacturing Services and Capabilities
Table 9.10  Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 10.1  Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 10.2  CellCAN: Overview
Table 10.3  Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 10.4  National Cell Manufacturing Consortium: Overview
Table 10.5  California Institute of Regenerative Medicine: Overview
Table 10.6  Cell Therapy Manufacturing: List of Gene and Cell Therapy Societies
Table 11.1  Cell Therapy Manufacturing: List of Collaborations
Table 12.1  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms: Average Capacity by Size of Manufacturers (Sample Data Set for Industry Players)
Table 12.2  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 12.3  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area: Average Capacity by Size of Manufacturers (Sample Data Set for Industry Players)
Table 12.4  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Size of Manufacturers
Table 12.5  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms: Average Capacity for Non-Industry Players
Table 12.6  Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area: Average Capacity for Non-Industry Players
Table 13.1  Costs Associated with Manufacturing of Stem Cell Therapies
Table 13.2  Price of Marketed Gene and Cell Therapies
Table 13.3  Price of Marketed Targeted Drugs
Table 13.4  Expert Opinions on Pricing of T-Cell Immunotherapies
Table 14.1 Active Clinical Studies for Cell Therapies
Table 14.2  Active Clinical Studies for Cell Therapies: Distribution by Patients Enrolled 
Table 14.3  Number of Active Clinical Trials for Cell Therapies, 2018-2030
Table 14.4  Number of Active Clinical Trials for Cell Therapies, 2018-2030: Distribution by Patients Enrolled
Table 18.1  Survey Response: Overview of the Participating Organizations
Table 18.2  Survey Response: Seniority Level of Respondents
Table 18.3  Survey Response: Type of Cell Therapy
Table 18.4  Survey Response: Scale of Operation
Table 18.5  Survey Response: Source of Cells
Table 18.6  Survey Response: Cell Culture System
Table 18.7  Survey Response: Fill / Finish Service
Table 19.1  Cell Therapies: Company Snapshots
Table 19.2  Center of Excellence for Cellular Therapy: Company Snapshots
Table 19.3  CiMaas: Company Snapshots
Table 19.4  Lion TCR: Company Snapshots
Table 19.5  Waisman Biomanufacturing: Company Snapshots
Table 19.6  YposKesi: Company Snapshots
Table 20.1  Cell Therapy Manufacturers: Distribution by Location of Headquarters
Table 20.2  Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Regions-wise)
Table 20.3  Cell Therapy Manufacturers: Distribution by Location of Manufacturing Facility (Countries-wise)
Table 20.4  Cell Therapy Manufacturers: Distribution by Type of Organization
Table 20.5  Cell Therapy Manufacturers: Distribution by Type of Cell Therapy
Table 20.6  Cell Therapy Manufacturers: Distribution by Immune Cells
Table 20.7  Cell Therapy Manufacturers: Distribution by Stem Cells
Table 20.8  Cell Therapy Manufacturers: Distribution by Purpose of Production
Table 20.9  Cell Therapy Manufacturers: Distribution by Scale of Operation
Table 20.10  Cell Therapy Manufacturers: Distribution by Source of Cells
Table 20.11 Cell Therapy Manufacturing: Distribution by Regulatory Authorities
Table 20.12  Cell Therapy Manufacturing: Comparative Analysis of Manual versus Automated Processes Based on Cost of Manufacturing per Batch
Table 20.13  Cell Therapy Manufacturing Partnerships: Cumulative Trend of by Year (2014-2018)
Table 20.14  Cell Therapy Manufacturing Partnerships: Distribution by Type of Partnership Model
Table 20.15  Cell Therapy Manufacturing Partnerships: Distribution by Year and Type of Partnership Model (2014-2018)
Table 20.16  Cell Therapy Manufacturing Partnerships: Distribution by Type of Cells
Table 20.17  Cell Therapy Manufacturing Partnerships: Distribution by Most Active Players
Table 20.18  Cell Therapy Manufacturing Partnerships: Regional Distribution
Table 20.19  Cell Therapy Manufacturing: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 20.20  Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Size of Manufacturers (Sample Data Set for Industry Players)
Table 20.21 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 20.22 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Scale of Operation
Table 20.23 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Location of Manufacturing Facility
Table 20.24 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area: Distribution by Size of Manufacturers (Sample Data Set for Industry Players)
Table 20.25 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Size of Manufacturers
Table 20.26 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Scale of Operation
Table 20.27 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Industry): Distribution by Location of Manufacturing Facility
Table 20.28 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry): Distribution by Scale of Operation
Table 20.29 Cell Therapy Manufacturing Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry): Distribution by Location of Manufacturing Facility
Table 20.30 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry): Distribution by Scale of Operation
Table 20.31 Cell Therapy Manufacturing Installed Global Capacity in Terms of Cleanroom Area (Non-Industry): Distribution by Location of Manufacturing Facility
Table 20.32 Overall Cell Therapy Manufacturing Market, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030 (USD Billion)
Table 20.33 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Type of Cell Therapy, 2018, 2025 and 2030
Table 20.34 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Source of Cells,  2018, 2025 and 2030
Table 20.35 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Scale of Operation, 2018, 2025 and 2030
Table 20.36 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Purpose of Manufacturing, 2018, 2025 and 2030 
Table 20.37 Cell Therapy Manufacturing Market, 2018-2030: Distribution by Regions, 2018, 2025 and 2030
Table 20.38 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
Table 20.39 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Source of Cells
Table 20.40 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Regions
Table 20.41 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
Table 20.42 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Source of Cells
Table 20.43 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Regions
Table 20.44 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Source of Cells
Table 20.45 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Regions
Table 20.46 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy)
Table 20.47 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Source of Cells
Table 20.48 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Regions
Table 20.49 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
Table 20.50 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Source of Cells
Table 20.51 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Regions
Table 20.52 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Source of Cells
Table 20.53 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative Scenario, Base Scenario, Optimistic Scenario, 2018-2030: Distribution by Regions
Table 20.54 Survey Analysis: Distribution by Type of Organization
Table 20.55 Survey Analysis: Distribution by Location of Manufacturing Facility
Table 20.56 Survey Analysis: Distribution by Seniority Level of Respondents
Table 20.57 Survey Analysis: Distribution by Type of Cell Therapy
Table 20.58 Survey Analysis: Distribution by Scale of Manufacturing
Table 20.59 Survey Analysis: Distribution by Source of Cells
Table 20.60 Survey Analysis: Distribution by Cell Culture System
Table 20.61 Survey Analysis: Distribution by Fill / Finish Service

List of Companies

The following companies and organizations have been mentioned in the report.

  1. 3P Biopharmaceuticals
  2. A2 Healthcare
  3. Accellta
  4. Acerta Pharma
  5. Adaptimmune
  6. Adva Biotechnology
  7. Advanced Cell Therapy Laboratory, Yale School of Medicine
  8. Advanced Regenerative Manufacturing Institute 
  9. Advent Bioservices 
  10. Agios Pharmaceuticals
  11. Ajinomoto
  12. Akron Biotech
  13. Alberta Cell Therapy Manufacturing, University of Alberta
  14. Allele Biotechnology & Pharmaceuticals
  15. Alliance for Regenerative Medicine
  16. AlloSource
  17. Altor BioScience
  18. American Productivity & Quality Center
  19. American Society of Gene and Cell Therapy
  20. American Society of Mechanical Engineers 
  21. Amgen
  22. Amsterdam Biotherapeutics Unit 
  23. Andalusian Initiative for Advanced Therapies
  24. Angiocrine Bioscience
  25. Anterogen
  26. Aokai (Suzhou) Biomedical
  27. apceth Biopharma
  28. Argos Therapeutics
  29. ARIAD Pharmaceuticals
  30. Asahi Glass Company
  31. Asterias Biotherapeutics
  32. AstraZeneca
  33. Asymptote
  34. Atara Biotherapeutics
  35. Athersys
  36. Atlantic Bio GMP
  37. ATVIO Biotechnology
  38. Australasian Gene and Cell Therapy Society
  39. Austrian Network for Gene Therapy
  40. Autolus
  41. Azellon Cell Therapeutics
  42. Bavarian Nordic
  43. Bayer
  44. Be The Match BioTherapies
  45. Bellicum Pharmaceuticals
  46. Berkeley Lights
  47. Bio Elpida
  48. BioCision
  49. Bioinova
  50. BioLife Solutions
  51. Biological and Cellular GMP Manufacturing Facility, City of Hope
  52. biologistex CCM
  53. BioNTech Innovative Manufacturing Services
  54. Biosafe Group
  55. bluebird bio
  56. Boehringer Ingelheim
  57. Bone Therapeutics 
  58. Brammer Bio
  59. Bristol-Myers Squibb 
  60. British Society for Gene and Cell Therapy
  61. California Institute of Regenerative Medicine 
  62. Cancer Research UK
  63. Capricor Therapeutics
  64. CardioCell
  65. Celgene
  66. Cell and Gene Therapy Catapult
  67. Cell Manipulation Core, Dana-Farber / Harvard Cancer Center
  68. Cell Medica
  69. Cell Tech Pharmed
  70. Cell Therapies
  71. Cell Therapy and Regenerative Medicine, University of Utah
  72. Cell Therapy Facility, UMC Utrecht 
  73. Cell Therapy Manufacturing Cooperative Research Center
  74. Cell Therapy Suite, University of Birmingham
  75. Cellab
  76. CellCAN
  77. Cellectis
  78. CELLforCURE
  79. Cellin Technologies
  80. Cells Cure Foundation
  81. Cells for Sight, Stem Cell Therapy Research Unit, University College London 
  82. Cellular Biomedicine Group 
  83. Cellular Therapeutics
  84. Cellular Therapy Core, University of Texas
  85. Cellular Therapy Integrated Services, Case Western Reserve University
  86. Celyad
  87. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  88. Center for Cell and Gene Therapy, Baylor College of Medicine
  89. Center for Gene and Cell Processing, Takara Bio
  90. Center for International Blood and Marrow Transplant Research
  91. Centre for Biological Engineering, Loughborough University
  92. Centre for Cell and Vector Production 
  93. Centre for Cell Manufacturing Ireland, NUI Galway
  94. Centre for Commercialization of Regenerative Medicine
  95. Centre for Stem Cell Research
  96. Centre for Commercialization of Cancer Immunotherapy (C3i)
  97. Centre multidisciplinaire de développement du génie tissulaire
  98. Centre of Genomics and Policy, McGill University
  99. Cesca Therapeutics 
  100. Chemometec
  101. Chiesi Farmaceutici
  102. Children’s Medical Research Institute
  103. Children's GMP, St. Jude Children's Research Hospital
  104. China Life Health Industry Group
  105. China Regenerative Medicine International
  106. CiMaas
  107. City of Hope Alpha Clinic for Cell Therapy
  108. Clinical Biomanufacturing Facility, University of Oxford
  109. Clinical Cell and Vaccine Production Facility 
  110. Clinical Research Facility, South London and Maudsley
  111. Closed Cell Systems
  112. Cognate BioServices
  113. Commonwealth Scientific and Industrial Research Organization 
  114. Cook MyoSite
  115. CRISPR Therapeutics
  116. Cryoport
  117. Cryosite
  118. CureCell
  119. Cynata Therapeutics
  120. Cytonome
  121. Cytori Therapeutics
  122. CyTuVax
  123. DanDrit Biotech
  124. DCPrime
  125. Dendreon 
  126. DiscGenics
  127. Eli Lilly
  128. EMERCell
  129. Emory Personalized Immunotherapy Core
  130. European Bank for induced pluripotent Stem Cells 
  131. European Society of Gene and Cell Therapy
  132. Federal Economic Development Agency for Southern Ontario 
  133. Ferrologix
  134. Fibrocell
  135. Finnish Gene Therapy Society
  136. Fisher BioServices
  137. FloDesign Sonics
  138. Fortuna Fix
  139. Fosun Pharma
  140. Foundation for the Accreditation of Cellular Therapy
  141. Foundation of Croatian Association for Regenerative Medicine and Stem Cell  Therapy
  142. Fraunhofer Institute for Cell Therapy and Immunology IZI
  143. French Society of Cellular and Gene Therapy
  144. Froceth
  145. FUJIFILM 
  146. FUJIFILM Cellular Dynamics
  147. Gamida Cell
  148. Gates Biomanufacturing Facility
  149. GC Cell
  150. GE Healthcare
  151. GenCure 
  152. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  153. Genentech
  154. Georgia Institute of Technology
  155. Georgia Research Alliance
  156. German Gene Therapy Society
  157. Gilead Sciences
  158. GlaxoSmithKline
  159. Glycostem Therapeutics
  160. GPB Scientific
  161. Gradalis
  162. Great Ormond Street Hospital Cellular Therapy Laboratories, University College  London
  163. Guy's and St Thomas' Facility
  164. Haematological Sciences, Institute of Cellular Medicine
  165. Harvard University Stem Cell Institute 
  166. Health Sciences Authority
  167. Hielscher Ultrasonics
  168. Histocell
  169. Hitachi Chemical Advanced Therapeutics Solutions
  170. Holostem Terapie Avanzate
  171. Hospital of University of Pennsylvania 
  172. Houston Methodist Hospital Foundation
  173. Houston Methodist Institute of Technology, Innovation and Education
  174. Houston Methodist Research Institute
  175. Human Islet and Cellular Transplant Facility
  176. Human Stem Cells Institute
  177. Immatics Biotechnologies
  178. ImmunoCellular Therapeutics
  179. Immunocore
  180. Immunovative Therapies 
  181. IncoCell Tianjin
  182. Innovate UK
  183. Innovative Cellular Therapeutics
  184. IntelliCell BioSciences
  185. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami 
  186. International Cellular Medicine Society
  187. International Society for Cancer Gene Therapy
  188. International Society for Cellular Therapy
  189. International Society for Stem Cell Research
  190. International Stem Cell Corporation
  191. Invetech
  192. Iovance Biotherapeutics
  193. IQVIA Stem Cell Center
  194. Irish Society for Gene and Cell Therapy
  195. Irish Stem Cell Foundation
  196. Israeli Society for Gene and Cell Therapy
  197. Isto Biologics
  198. Japan Society for Gene Therapy
  199. Japan Tissue Engineering 
  200. Jazz Pharmaceuticals
  201. JCR Pharmaceuticals
  202. John Goldmann Centre for Cellular Therapy, Imperial College London
  203. Juno Therapeutics
  204. JW CreaGene
  205. Kawasaki Heavy Industries
  206. KBI Biopharma
  207. Kiadis Pharma 
  208. Kids Research Institute
  209. Kite Pharma
  210. KMC Systems 
  211. Kolon TissueGene
  212. Korean Society of Gene and Cell Therapy
  213. Laboratory for Cell and Gene Medicine, University of Stanford
  214. Lexicon Pharmaceuticals
  215. Lion TCR
  216. Lonza
  217. Maisonneuve-Rosemont Hospital
  218. Marken
  219. MaSTherCell
  220. Mayo Clinic Center for Regenerative Medicine 
  221. MedCision
  222. Medigene
  223. MEDINET
  224. Medipost
  225. Medistem Panama (Stem Cell Institute)
  226. MedPost
  227. MedStar Georgetown University Hospital
  228. Merck
  229. Mesoblast
  230. Michael Smith Laboratories, University of British Columbia
  231. Millennium Pharmaceuticals
  232. Millipore Sigma
  233. Miltenyi Biotec
  234. MNX Global Logistics
  235. Moffitt Cancer Center
  236. Molecular and Cellular Therapeutics, University of Minnesota
  237. MolMed
  238. Mustang Bio
  239. Nantes University Hospital
  240. National Cell Manufacturing Consortium 
  241. National Centre for Biomedical Engineering Sciences
  242. National Eye Institute
  243. National Gene Vector Laboratory 
  244. National Institute of Health Research 
  245. National Institute of Standards and Technologies
  246. National Stem Cell Foundation
  247. National Stem Cell Foundation of Australia 
  248. Neon Therapeutics
  249. Netherlands Cancer Institute 
  250. Networks of Centres of Excellence
  251. Neuralstem
  252. NewLink Genetics
  253. NHSBT Birmingham 
  254. Nikon 
  255. Nikon CeLL innovation
  256. Northwest Biotherapeutics
  257. Norwegian Radium Hospital 
  258. Novadip
  259. Novartis 
  260. NuVasive
  261. Octane Medical Group
  262. Oncobiomed
  263. Ontario Institute of Regenerative Medicine
  264. Onyx Pharmaceuticals
  265. Orchard Therapeutics
  266. Orgenesis
  267. Orthofix 
  268. Ospedale Pediatrico Bambino Gesù 
  269. Ottawa Hospital Research Institute, University of Ottawa
  270. Oxford BioMedica
  271. Oxford MEStar 
  272. Pall Corporation
  273. PAREXEL
  274. PCI Services
  275. PCT Cell Therapy Services
  276. Peter Couche Foundation
  277. Peter MacCallum Cancer Centre
  278. Pfizer
  279. PharmaBio
  280. PharmaCell
  281. Pharmicell
  282. Pluristem Therapeutics
  283. Praxis Pharmaceutical
  284. Production Assistance for Cellular Therapies
  285. Promethera Biosciences
  286. Provia Laboratories
  287. Puma Biotech
  288. Q-GEN Cell Therapeutics, QIMR Berghofer Medical Research Institute
  289. Rayne Cell Therapy Suite, King's College London
  290. Regenerative Medicine Foundation
  291. Regenerative Medicine Institute
  292. Regenesys
  293. Regeneus
  294. Reliance Life Sciences
  295. ReNeuron
  296. RepliCel
  297. Research and Development Center for Cell Therapy, Foundation for Biomedical  Research and Innovation
  298. Riyadh Pharma
  299. Robertson Clinical and Translational Cell Therapy, Duke University
  300. Roche Diagnostics
  301. Rooster Bio
  302. Roslin Cells
  303. Roswell Park Cancer Institute
  304. Royal Free Hospital, Centre for Cell and Gene Tissue Therapeutics
  305. Royal Prince Alfred Hospital
  306. Saint-Gobain
  307. SanBio 
  308. Sartorius Stemdim
  309. SAVSU Technologies 
  310. Scinogy
  311. Scottish National Blood Transfusion Service Cellular Therapy Facility
  312. Servier
  313. Shanghai Sunway Biotech
  314. Shenzhen SiBiono GeneTech
  315. Shibuya Corporation
  316. Sistemic
  317. Smilow Translational Research Center
  318. Smith & Nephew 
  319. SOTIO
  320. Spanish Society of Gene and Cell Therapy
  321. Spark Therapeutics
  322. Stage Cell Therapeutics
  323. Stanford Children's Health, Stanford Health Care 
  324. Stanford School of Medicine
  325. Stemedica Cell Technologies
  326. Sumitomo Dainippon Pharma
  327. Swedish Society for Gene and Cell Therapy
  328. Sydney Cell and Gene Therapy 
  329. SynGen
  330. Takeda Pharmaceutical
  331. TAP Biosystems
  332. TargetAMD
  333. TC Biopharm
  334. T-Cell Factory 
  335. Terumo 
  336. Terumo BCT
  337. TESARO
  338. Texas Children’s Hospital 
  339. Texas Medical Center
  340. The Children’s Hospital at Westmead
  341. The Elisa Linton Center for Rare Disease Therapies
  342. The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan  Kettering Cancer Center
  343. The Netherlands Society of Gene and Cell Therapy
  344. The New York Stem Cell Foundation
  345. The Ottawa Hospital Research Institute
  346. The Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  347. The University of Texas Health Science Center  
  348. Therapeutic Cell Production Core, Seattle Children's Hospital
  349. Thermo Fisher Scientific
  350. ThermoGenesis
  351. TiGenix
  352. Tokyo Electron
  353. TrakCel
  354. Trinity Partners
  355. Turkish Society for Gene and Cell Therapy
  356. TVAX Biomedical
  357. TxCell
  358. Tyne Hospitals NHS Foundation Trust
  359. UC Davis GMP Laboratory
  360. UCLA Human Gene and Cell Therapy
  361. UCLA-UCI Alpha Stem Cell Clinic 
  362. UK Stem Cell Foundation
  363. University Hospital Basel
  364. University Medical Center Groningen 
  365. University of California
  366. University of Leeds
  367. University of Manchester 
  368. University of Newcastle
  369. University of North Carolina Lineberger Comprehensive Cancer Center 
  370. University of Tennessee
  371. Upstate Stem Cell cGMP Facility, University of Rochester
  372. Vaccinogen 
  373. Valeant Pharmaceuticals
  374. Vecura, Karolinska University Hospital
  375. Vericel
  376. Vineti
  377. Vitruvian Networks
  378. VivaBioCell
  379. Waisman Biomanufacturing
  380. Westmead Hospital
  381. Westmead Millennium Institute
  382. World Courier
  383. WuXi Advanced Therapies
  384. WuXi AppTec
  385. Wyeth
  386. Xellbiogene
  387. YposKesi
  388. Zelluna Immunotherapy
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com